– Global Healthcare Opportunities (GHO Capital Management Limited and GHO Capital Partners Advisory Ltd.), a European specialist investor in global healthcare, announced the final close of its fourth fund, GHO Capital IV LP, raising over €2.5 billion (~$2.9 billion).
– Fund IV attracted both existing and more than 30 new institutional investors from Europe, North America, Asia Pacific, and the Middle East.
– The new fund is GHO’s largest to date, 25% larger than its predecessor, bringing total assets under management to approximately €9 billion.
– GHO is now the largest healthcare specialist private equity firm headquartered in Europe.
– Fund IV will continue GHO’s strategy of scaling innovative regional leaders into vertically integrated platforms with global reach, focusing on:
▪️BioPharma
▪️MedTech
▪️Advisory & Data
▪️Life Science Tools & Diagnostics
▪️HealthTech
– The fund aims to deliver better, faster, and more accessible healthcare through operational and strategic growth.
– In 2025, GHO signed three new platform investments and several add-on acquisitions:
▪️Avid Bioservices – CDMO for biologics development and CGMP manufacturing
▪️Scientist.com – AI-powered R&D orchestration platform for pharma and biotech
▪️FotoFinder Systems – manufacturer of advanced skin diagnostics and imaging solutions
– Since closing Fund III in 2021, GHO has expanded its transatlantic presence with 19 new hires, growing to over 75 professionals in Europe and the US.
– The firm strengthened its leadership with a new Partner in 2024 and five new Operating Partners and Senior Advisors with deep healthcare expertise.
– Managing Partners Mike Mortimer, Alan MacKay, and Andrea Ponti highlighted the “golden era of healthcare innovation” driven by science, digital technologies, and data, and credited GHO’s success to its strategy, transatlantic reach, and consistent performance.
